Who Paid My Doc
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib
ClinicalTrials.gov NCT02614794
Research payments
$8,849,028
Through program year 2023, $8,849,028 in research payments was reported against Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib, across 2,470 payments, paid by Seattle Genetics, Inc..
- Paid by
- Seattle Genetics, Inc.
- ClinicalTrials.gov
- NCT02614794
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $315,946 | 43 |
| 2022 | Research | $404,857 | 158 |
| 2021 | Research | $864,045 | 369 |
| 2020 | Research | $2,381,475 | 674 |
| 2019 | Research | $4,882,704 | 1,226 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Cheryl Aylesworth Rockville, MD Named on 148 payments
- Susan Brown Skokie, IL Named on 130 payments
- Marilyn Raymond West Palm Beach, FL Named on 120 payments
- Gail Wright Hudson, FL Named on 111 payments
- Patricia Rodriguez Arlington, VA Named on 74 payments
- William Houck Winchester, VA Named on 60 payments
- Michelina Cairo Houston, TX Named on 57 payments
- Erika Hamilton Nashville, TN Named on 53 payments
- Inna Shmerlin Dallas, TX Named on 43 payments
- Leonard Klein Niles, IL Named on 40 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.